Select therapeutic use:
Indications for ARGATROBAN:
Prophylaxis and treatment of thrombosis in heparin-induced thrombocytopenia (HIT) or in those with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
≥18yrs: HIT: Discontinue heparin and obtain baseline aPTT. Initially 2micrograms/kg per minute by continuous IV infusion; check aPTT 2 hrs after starting; titrate to 1.5–3x baseline aPTT (max 100seconds); max 10micrograms/kg per minute. PCI: initially 25micrograms/kg per minute by IV infusion, and 350micrograms/kg bolus by large bore IV line over 3–5minutes; titrate based on activated clotting time (ACT) to therapeutic ACT of 300–450seconds. For both: hepatic impairment: reduce dose (see literature).
<18yrs: not established.
Overt major bleeding. Concomitant other parenteral anticoagulants.
Increased bleeding risk (eg, unexpected decreases in hematocrit or BP, severe hypertension, recent lumbar puncture, spinal anesthesia, major surgery, bleeding disorders, GI lesions). Pregnancy (Cat.B). Nursing mothers: not recommended.
Increased risk of bleeding with thrombolytics (eg, t-PA, streptokinase), Vit. K antagonists (eg, warfarin), heparin, antiplatelets, GP IIb/IIIa blockers (eg, eptifibatide).
Hemorrhagic events, chest pain, dyspnea, cough, hypotension, rash, fever, GI upset, cardiac arrest, ventricular tachycardia, others.
Single-use vial (2.5mL)—1